Natco Pharma Stock Price - ₹838.30 | Healthcare

‌
‌
‌

Company insights, generated from the most recent coverage.

Multi-facility strategy (Hyderabad + Vizag + CMOs) enables seamless product transfers, ensuring supply continuity and mitigating revenue impact during regulatory issues at any single site.
Read more
Received tentative FDA approval for Olaparib tablets (bioequivalent to AstraZeneca's Lynparza® with ~$1.4B US sales), strengthening FTF pipeline with over 20 First-to-File products including 17 approved.
Read more
FDA Form 483 with 4 procedural observations at Visakhapatnam FDF plant (Aug 2026); management confident in timely resolution, minimizing disruption risk.
Read more

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Natco Pharma shows steady growth in domestic and API segments, but international sales and overall profits face headwinds.

API revenue grows from ₹526 Cr in Q1 FY26 to ₹667 Cr in Q1 FY27, showing steady segment expansion.

Consolidated revenue drops from ₹13,906 Cr in Q1 FY26 to ₹7,944 Cr in Q1 FY27, highlighting top-line contraction.

Domestic formulations revenue rises from ₹1,070 Cr in Q1 FY26 to ₹1,364 Cr in Q1 FY27, confirming strong local demand.

International formulations revenue falls from ₹11,265 Cr in Q1 FY26 to ₹4,771 Cr in Q1 FY27, pointing to export headwinds.

Share of profit from associates jumps from ₹11 Cr in Q3 FY26 to ₹843 Cr in Q1 FY27, boosting consolidated earnings.

Profit after tax declines from ₹4,803 Cr in Q1 FY26 to ₹1,222 Cr in Q1 FY27, showing sustained earnings pressure.

Total expenses fall from ₹7,579 Cr in Q1 FY26 to ₹5,487 Cr in Q1 FY27, reflecting disciplined cost control.

Finance cost rises from ₹32 Cr in Q1 FY26 to ₹130 Cr in Q1 FY27, increasing debt servicing burden.

Crop health sciences revenue recovers from ₹285 Cr in Q3 FY26 to ₹408 Cr in Q1 FY27, indicating seasonal strength.

EBITDA slips from ₹6,327 Cr in Q1 FY26 to ₹2,457 Cr in Q1 FY27, reflecting margin compression.

‌
‌
‌

In the news

Natco Pharma gets 4 FDA observations, invests $14M in eGenesis

Natco Pharma Q1 results: Net profit falls 57% to ₹207 cr, shares drop 5%

Natco Challenges Novartis's Second Ribociclib Patent in Delhi HC

Natco Pharma surges 4.25% on US FDA approval for Olaparib tablets

Natco Pharma completes ₹1,060 cr acquisition of 49% Adcock Ingram stake

Q1 FY27 Earnings Preview: Tech, FMCG, and Wealth Management Trends

Natco Pharma shares gain 2.5% on ₹2,500 cr South Africa investment

Lupin gets USFDA approval for Ranluspec biosimilar and Eribulin injection

Brokerages Eye Dixon Tech, Natco Pharma, Ather Energy for Trade

Natco Pharma stock crashes 20% in 2 days after Q4 profit drops 64%

Natco Pharma demergers agrochemicals, shares up 2.18%

NATCO Pharma board to approve agrochemicals demerger on March 24

Natco Pharma shows bullish rounding bottom pattern

Natco Pharma launches Pomalidomide capsules in US market

Eris-Natco semaglutide partnership drives 11% stock surge

Natco Pharma gets CDSCO nod for generic semaglutide launch amid market boom

India-US trade deal finalized: $500B commitment with market access expansion

NATCO Pharma gets USFDA approval for generic cancer drug

Natco Pharma